Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Adults

In brief

This study is a single-center, randomized, open-label, active and placebo-controlled, parallel-group, conducted in healthy male volunteers who have been shown to be extensive metabolizers of dextromethorphan.

Key facts

Study ID

NCT01367535

Run by

Bausch Health Americas, Inc.

People needed

54

Starts

2006-03-01

Expected to finish

2006-08-01

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy males between the ages of 18 and 55
• Non-Smokers
• Body weight range form 154-220 lbs
• No history of clinically significant metabolic disorders.

You may not qualify if…

• Any history of low CYP450 2D6 activity
• History of alcohol abuse or recreational drugs
• History of any clinically significant disease or condition affecting a major organ system
• Donation or loss of blood, 60 days proceeding to screening visit.

Where it is running

• Progenics Pharmaceuticals — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.